Following the closing of its initial public offering, Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, has restructured its board with members with operating experience.
Venture capital representatives, Dr. Shermaine Tilley (Managing Partner at CTI Life Sciences Fund), Dion Madsen (Senior Managing Partner at BDC Capital Healthcare Fund), along with Dr. Kerry Blanchard (SVP, Medicines Development, Eli Lilly and Company), have resigned from Zymeworks’ board of directors.
“We would like to thank Shermaine, Dion, and Kerry for their years of invaluable service,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “Their insights have helped shape the company that Zymeworks is today, and each of their contributions will be felt for years to come. We wish them the best of luck in their future endeavors.”
Following Zymeworks’ initial public offering, its board of directors is comprised of: Nick Bedford (Chair), Noel Hall (Managing Partner of MacHall Group), Kenneth Hillan (former CEO of Achaogen, Inc.), Hollings Renton (former CEO of Onyx Pharmaceuticals, Inc.), Ali Tehrani and Lota Zoth (former CFO of MedImmune, Inc).